2025 • Volume • • Electronic publication date:

Australian Gonococcal Surveillance Programme Annual Report, 2023

Monica M Lahra, Sebastiaan J van Hal and Tiffany R Hogan for the National Neisseria Network, Australia

# Abstract

The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in *Neisseria gonorrhoeae* for more than 40 years. In 2023, a total of 10,105 isolates from patients in the public and private sectors, in all jurisdictions, were tested for *in vitro* antimicrobial susceptibility by standardised methods. Nationally, in 2023, the AGSP captured antimicrobial susceptibility data for 25% of all gonococcal infection notifications.

The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin. In 2023, of *N. gonorrhoeae* isolates tested, 0.22% (22/10,105) met the WHO criterion for ceftriaxone decreased susceptibility (DS), defined as a minimum inhibitory concentration (MIC) value ≥ 0.125 mg/L.

Resistance to azithromycin was reported in 4.5% of *N. gonorrhoeae* isolates, proportionally stable since 2019. There were 27 isolates (0.27%) with high-level resistance to azithromycin (MIC value ≥ 256 mg/L) reported in Australia: Victoria (13), New South Wales (11), non-remote Western Australia (2) and Queensland (1). This is the highest number ever detected and reported in a twelve-month period by the AGSP.

In 2023, penicillin resistance was found in 30.7% of gonococcal isolates, and ciprofloxacin resistance in 60.3%, although there was considerable variation by jurisdiction. In some remote settings, penicillin remains recommended as part of an empiric therapy strategy. However, in 2023, in remote Northern Territory, five penicillin-resistant isolates were reported; and in remote Western Australia, 14.1% of gonococcal isolates (10/71) were penicillin resistant. In addition, there were eight ciprofloxacin-resistant isolates reported from remote Northern Territory; ciprofloxacin resistance rates have increased in remote Western Australia (16/71; 22.5%). This increase in penicillin-resistant *Neisseria gonorrhoeae* in the Northern Territory has effected a change in gonococcal treatment recommendations.

Keywords: antimicrobial resistance; disease surveillance; gonococcal infection; Neisseria gonorrhoeae

# Introduction

The National Neisseria Network (NNN) is a collaborative network, established in the late 1970s, that comprises jurisdictional *Neisseria* reference laboratories across Australia. The NNN laboratories provide reference-level services for the pathogenic *Neisseria* species: *N. gonorrhoeae* (NG) and *N. meningitidis*. The Australian Gonococcal Surveillance Programme (AGSP) is a key activity of the NNN and has been operational for more than 40 years.1 Over these decades, the AGSP has reported the emergence of resistance to all antibiotics used in the treatment of gonorrhoea, and has detected and reported multi- and extensively-drug-resistant gonococcal strains in recent years. In 2017, the first evidence of sustained spread of multi-drug-resistant gonorrhoea was reported,2 followed in 2018 by coincident reports from Australia and the United Kingdom of the first extensively-drug-resistant *N. gonorrhoeae* isolates.3–5 The emergence of NG antimicrobial resistance (AMR) in Australia has largely occurred following introduction of multi-resistant strains from overseas.5,6 The importation and spread of ceftriaxone-resistant gonococcal strains, and/or of new resistance developing, remains an ongoing concern for disease control strategies, and is a focus of the work of the NNN.

The background rate of isolates in Australia with decreased susceptibility to ceftriaxone (defined as a minimum inhibitory concentration (MIC) value ≥ 0.125 mg/L) has remained low, and relatively stable, since the introduction of dual therapy for gonorrhoea in 2014 (ranging from 0.86% to 1.8%). Continuous AMR surveillance remains imperative to detect the emergence and spread of resistant strains, endangering empirical therapeutic regimens.6,7 The increased proportion of gonococcal isolates with azithromycin resistance in recent years has also added to concerns about management strategies, and continues to be monitored.

Notification rates of gonococcal infections in Australia increased by 114% between 2013 and 2019 (from 66.1 to 141.5 per 100,000 population per year), and then declined by 23% coincident with the coronavirus disease 2019 (COVID-19) restrictions in 2019 to 2021.8 In 2022, the notifications increased by 22% (133.8 per 100,000 population) and rose again in 2023 by 13.5% (151.8 per 100,000 population).8,9 Gonococcal disease rates in the Aboriginal and Torres Strait Islander population are markedly higher than in the non-Indigenous population (547.1 per 100 000 population, five times higher than that of the non-Indigenous population at 108.3 per 100 000 population) in 2023 and were highest in remote and very remote areas (738.6 per 100,000 population).8 Notwithstanding the higher gonococcal disease rates in such regions, historically NG AMR in remote and very remote areas has remained low. In 2023, increasing notifications of penicillinase-producing *Neisseria gonorrhoeae* in the Northern Territory has led to treatment recommendations centred on oral penicillin to change to dual therapy with ceftriaxone and azithromycin.10

In recent years, the heightened international awareness of gonococcal disease has coincided with increased molecular diagnoses replacing bacterial culture and antimicrobial susceptibility testing (AST). The corollary of this is a reduction in gonococcal isolates available for AMR surveillance.8,11 Molecular tests for antimicrobial resistance detect known genetic targets associated with resistance; however, these assays do not detect novel resistance mechanisms. Uniquely, in some remote regions of Australia, molecular assays are used to detect penicillin resistance in NG,12,13 the first documented use of such testing for NG AMR detection and surveillance.13,14 These data inform local treatment guidelines.14

Strategies for treatment and control of gonorrhoea are based on regimens effecting cure in a minimum of 95% of cases. Surveillance data of antibiotics in clinical use are critical to monitor AMR; to detect imported or novel resistance; and to inform treatment guidelines.12 The World Health Organization (WHO) has called for enhanced surveillance as a fundamental component of its Global Action Plan to control the spread and impact of gonococcal AMR.15

# Methods

Gonorrhoea infections are notifiable under legislation in Australia to the National Notifiable Diseases Surveillance System (NNDSS). The isolates tested by the NNN, and reported by the AGSP, represent a proportion of the total number of notified cases. The NNN laboratories test gonococcal isolates for susceptibility to ceftriaxone, azithromycin, penicillin, ciprofloxacin, spectinomycin and tetracycline. In addition, many NNN laboratories are testing gentamicin; these data were first reported by the AGSP in 2020, and reporting continues in 2023.

Antimicrobial susceptibility testing is performed using standardised methodology to determine the minimum inhibitory concentration (MIC) value, the lowest antibiotic concentration that inhibits *in vitro* growth under defined conditions. The coordinating lab for the NNN, the World Health Organization Collaborating Centre for Sexually Transmitted Infection and Antimicrobial Resistance (WHO CC, Sydney), conducts a program-specific quality assurance program.16 Gonococcal AST data from each jurisdiction are submitted quarterly to the WHO CC, Sydney. Where available, the AGSP collects data on the sex of the patient; the country of acquisition of infection; and the site of isolation of gonococcal isolates. Data collected across jurisdictions are predominantly from urban centres. Data from the Northern Territory and Western Australia are further divided into non-remote and remote regions determined at the jurisdictional level.

# Results

## Proportion of gonococcal infections with antimicrobial susceptibility testing

In 2023, there were 40,429 gonococcal infections notified in Australia;9 and of these, 10,105/40,429 (25%) had isolates available for AST performed by the NNN laboratories (Table 1). This is reflected in Figure 1, which plots AGSP (culture-confirmed cases) against national notification data (which includes both the AGSP and culture-independent diagnosis).


Across jurisdictions, the proportion of diagnoses made by culture varies, ranging from 8% to 56% as shown in Table 1. The lowest proportion is from the remote and very remote communities of the Northern Territory and Western Australia. The proportion is highest from the Australian Capital Territory, and likely reflects the small number of notifications in that jurisdiction.

Table 1: Number of Australian Gonococcal Surveillance Programme gonococcal isolates tested as a proportion of National Notifiable Diseases Surveillance System (NNDSS) gonorrhoea notifications,a Australia, 2023, by state or territory

| State or territory | Number of isolates tested | Number of cases notified | Number of isolates tested/Number of cases notified (%) |
| --- | --- | --- | --- |
| Australian Capital Territory | 270 | 484 | 56% |
| New South Wales | 3,588 | 12,457 | 29% |
| Northern Territory | 205 | 2,482 | 8% |
| Queensland | 1,534 | 7,549 | 20% |
| South Australia | 589 | 2,267 | 26% |
| Tasmania | 136 | 367 | 37% |
| Victoria | 2,745 | 10,090 | 27% |
| Western Australia | 1,038 | 4,733 | 22% |
| Australia | 10,105 | 40,429 | 25% |

a Source: National Communicable Disease Surveillance Dashboard (https://nindss.health.gov.au/pbi-dashboard/). Accessed 13 March 2024.9

Figure 1: Number of gonococcal disease cases reported to the National Notifiable Diseases Surveillance System,a compared with *Neisseria gonorrhoeae* isolates available for laboratory testing by the Australian Gonococcal Surveillance Programme, Australia, 1991–2023



a Source: National Communicable Disease Surveillance Dashboard (https://nindss.health.gov.au/pbi-dashboard/). Accessed 13 March 2024.9

## Gonococcal isolates, Australia, 2023, by sex, site and jurisdiction tested

There were 7,731 isolates tested in 2023 from males (76.5%) and 2,283 (22.6%) from females (Table 2). There were 91 isolates (0.90%) from patients whose sex was not recorded or recorded as ‘other’. The proportion of gonococcal isolates from males and females has remained stable over recent years (2009–2021), ranging between 17% and 22% for females and between 78% and 83% for males.17 The infected site was reported as ‘other’ or not specified for 281 isolates from males and for 92 isolates from females (Table 2). Isolates from urine samples were regarded as genital tract isolates.

## Antimicrobial resistance profile of *Neisseria gonorrhoeae*

For 2023, the numbers and proportions of gonococcal isolates resistant to azithromycin, ciprofloxacin and penicillin, are shown in Table 3. There continues to be variation across jurisdictions, as well as in remote settings when compared to non-remote settings.

Table 2: Gonococcal isolates, Australia, 2023, by sex, site and jurisdictiona tested

| Sex | Site | ACTa | NSW | NT | Qld | SA | Tas. | Vic. | WA | Australia |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Male** | Genital | 100 | 1,400 | 112 | 692 | 265 | 52 | 813 | 550 | 3,984 |
| Rectal | 53 | 929 | 11 | 210 | 82 | 35 | 714 | 62 | 2,096 |
| Pharynx | 56 | 554 | 10 | 94 | 28 | 17 | 541 | 42 | 1,342 |
| DGIb | 1 | 8 | 3 | 8 | 0 | 0 | 6 | 2 | 28 |
| Other/NSc | 0 | 39 | 1 | 35 | 37 | 1 | 156 | 12 | 281 |
| **Total** | **210** | **2,930** | **137** | **1,039** | **412** | **105** | **2,230** | **668** | **7,731** |
| **Female** | Genital | 39 | 515 | 65 | 425 | 149 | 28 | 350 | 335 | 1,906 |
| Rectal | 6 | 17 | 0 | 9 | 7 | 0 | 16 | 3 | 58 |
| Pharynx | 8 | 72 | 1 | 32 | 8 | 0 | 72 | 20 | 213 |
| DGI | 0 | 4 | 1 | 7 | 0 | 0 | 1 | 1 | 14 |
| Other/NS | 0 | 16 | 0 | 20 | 7 | 3 | 36 | 10 | 92 |
| **Total** | **53** | **624** | **67** | **493** | **171** | **31** | **475** | **369** | **2,283** |
| **Other** | Genital | 2 | 15 | 1 | 0 | 2 | 0 | 14 | 1 | 35 |
| Rectal | 2 | 4 | 0 | 0 | 1 | 0 | 16 | 0 | 23 |
| Pharynx | 2 | 11 | 0 | 0 | 0 | 0 | 7 | 0 | 20 |
| DGI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other/NS | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| **Total** | **7** | **30** | **1** | **0** | **3** | **0** | **38** | **1** | **80** |
| **Unknown** | Genital | 0 | 2 | 0 | 2 | 1 | 0 | 2 | 0 | 7 |
| Rectal | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 3 |
| Pharynx | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| DGI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other/NS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Total** | **0** | **4** | **0** | **2** | **3** | **0** | **2** | **0** | **11** |
| Total |  | 270 | 3,588 | 205 | 1,534 | 589 | 136 | 2,745 | 1,038 | 10,105 |

a ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic.: Victoria; WA: Western Australia.

b DGI: disseminated gonococcal infection.

c NS: not specified.

Table 3: Number and proportion (%) of gonococcal isolates with resistance to azithromycin, ciprofloxacin and penicillin reported, Australia, 2023, by state or territory

| State or territory | Number of isolates tested | Resistance | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Azithromycin | | Ciprofloxacin | | Penicillin | |
| n | % | n | % | n | % |
| Australian Capital Territory | 270 | 5 | 1.9 | 158 | 58.5 | 95 | 35.2 |
| New South Wales | 3,588 | 165 | 4.6 | 2,399 | 66.9 | 1,021 | 28.5 |
| Queensland | 1,534 | 41 | 2.7 | 829 | 54.0 | 487 | 31.7 |
| South Australia | 589 | 17 | 2.9 | 255 | 43.3 | 170 | 28.9 |
| Tasmania | 136 | 8 | 5.9 | 75 | 55.1 | 42 | 30.9 |
| Victoria | 2,745 | 159 | 5.8 | 1,785 | 67.9 | 960 | 36.5 |
| Northern Territory non-remote | 105 | 4 | 3.8 | 32 | 30.5 | 9 | 8.6 |
| Northern Territory remote | 100 | 0 | 0 | 8 | 8.0 | 5 | 5.0 |
| Western Australia non-remote | 967 | 57 | 5.9 | 539 | 55.7 | 303 | 31.3 |
| Western Australia remote | 71 | 2 | 3 | 16 | 22.5 | 10 | 14.1 |
| Australia | 10,105 | 458 | 4.5 | 6,096 | 60.3 | 3,102 | 30.7 |

### Ceftriaxone

Gonococcal isolates with ceftriaxone MIC values ≥ 0.125 mg/L are considered to have decreased susceptibility in accordance with WHO guidelines,15 and are reported by the AGSP; in addition, isolates with a ceftriaxone MIC value ≥ 0.064 mg/L have been detected and reported in Australia since 2001. The proportion reported by the AGSP, of isolates with ceftriaxone MIC ≥ 0.064 mg/L, increased to 4.4% in 2012 before doubling to 8.8% in 2013. However, from 2014, coincident with the introduction of dual ceftriaxone and azithromycin therapy, there has been an overall declining trend in the proportion of gonococcal isolates with decreased susceptibility to ceftriaxone in Australia, as shown in Table 4 and 5.

In 2022 there was a surge in the number and proportion of isolates with ceftriaxone MIC values of 0.064 and 0.125 mg/L, reported in the majority from New South Wales (Table 4 and Table 5). Genomic investigations in New South Wales identified expansion of a clone of limited genomic diversity of multilocus sequence type (MLST) ST-7827, detected in male and female patients across the state.18 All these were susceptible to azithromycin, but resistant to ciprofloxacin. ST-7827 isolates were also reported in 2022 in lower numbers from South Australia.18,19 In 2023, the proportion of *N. gonorrhoeae* with these MIC values fell to 3.29% (332/10,105) and 0.10% (10/10,105), respectively.

Table 4: Number and proportion (%) of gonococcal isolates with ceftriaxone MIC values ≥ 0.064 mg/L, Australia, 2014 to 2023, by state or territory

| State or territory | Decreased susceptibility to ceftriaxone (MIC ≥ 0.064 mg/L) | | | | | | | | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2014 | | 2015 | | 2016 | | 2017 | | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2023 | |
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| Australian Capital Territory | 2 | 2.7 | 0 | 0 | 1 | 0.9 | 0 | 0 | 4 | 1.9 | 1 | 0.5 | 0 | 0 | 1 | 0.5 | 6 | 2.8 | **1** | **0.4%** |
| New South Wales | 119 | 7.1 | 52 | 2.7 | 45 | 2.0 | 13 | 0.5 | 30 | 0.8 | 44 | 1.2 | 30 | 1.2 | 18 | 0.9 | 332 | 12 | **238** | **6.6%** |
| Queensland | 21 | 3.2 | 7 | 1.0 | 32 | 3.7 | 11 | 0.9 | 18 | 1.3 | 16 | 1.0 | 17 | 1.1 | 4 | 0.4 | 8 | 0.6 | **32** | **2.1%** |
| South Australia | 2 | 1.0 | 9 | 3.6 | 2 | 0.6 | 2 | 0.6 | 3 | 1.3 | 9 | 1.6 | 0 | 0 | 4 | 1.4 | 18 | 3.9 | **8** | **1.4%** |
| Tasmania | 0 | 0 | 0 | 0 | 1 | 3.6 | 0 | 0 | 4 | 7.3 | 1 | 2.1 | 0 | 0 | 1 | 1.4 | 0 | 0 | **0** | **0%** |
| Victoria | 95 | 6.6 | 25 | 1.5 | 19 | 1.1 | 48 | 2.1 | 83 | 3.2 | 42 | 1.6 | 18 | 1.1 | 25 | 1.3 | 82 | 3.3 | **66** | **2.4%** |
| Northern Territory non-remote | 3 | 3.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1.1 | **3** | **2.9%** |
| Northern Territory remote | 1 | 0.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | **0** | **0%** |
| Western Australia non-remote | 14 | 3.6 | 5 | 1.3 | 9 | 1.3 | 9 | 1.4 | 14 | 2.1 | 11 | 1.5 | 3 | 0.4 | 1 | 0.2 | 9 | 1.9 | **6** | **0.6%** |
| Western Australia remote | 1 | 0.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2.4 | 0 | 0 | 0 | 0 | 0 | 0 | **0** | **0%** |
| Australia | 258 | 5.4 | 98 | 1.8 | 109 | 1.7 | 83 | 1.1 | 156 | 1.7 | 126 | 1.3 | 68 | 0.9 | 54 | 0.9 | 456 | 5.6 | 354 | 3.5% |

Table 5: Proportion (%) of gonococcal isolates tested in Australia with ceftriaxone MIC values at 0.064 mg/L and ≥ 0.125 mg/L14 and resistance to azithromycin, 2010 to 2023

| Year | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of isolates tested nationally | 4,100 | 4,230 | 4,718 | 4,897 | 4,804 | 5,411 | 6,378 | 7,835 | 9,006 | 9,668 | 7,222 | 6,254 | 8,199 | **10,105** |
| Ceftriaxone MIC 0.064 mg/L | 4.80% | 3.20% | 4.10% | 8.20% | 4.80% | 1.70% | 1.65% | 1.02% | 1.67% | 1.19% | 0.87% | 0.83% | 5.05% | **3.29%** |
| Ceftriaxone DSa MIC ≥ 0.125 mg/L | 0.10% | 0.10% | 0.30% | 0.60% | 0.60% | 0.10% | 0.05% | 0.04% | 0.06% | 0.11% | 0.07% | 0.03% | 0.51% | **0.22%** |
| **Ceftriaxone total (MIC values ≥ 0.064 mg/L)** | **4.90%** | **3.30%** | **4.40%** | **8.80%** | **5.40%** | **1.80%** | **1.70%** | **1.06%** | **1.73%** | **1.30%** | **0.94%** | **0.86%** | **5.56%** | **3.51%** |
| Azithromycin resistance | n/a | 1.1% | 1.3% | 2.1% | 2.5% | 2.6% | 5.0% | 9.3% | 6.2% | 4.6% | 3.9% | 4.7% | 3.9% | **4.5%** |

a DS: decreased susceptibility.

Table 6: Number and proportion (%) of gonococcal isolates with resistance to azithromycin, Australia, 2012 to 2023, by state or territory

| Jurisdictiona | Azithromycin resistance | | | | | | | | | | | | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2012 | | 2013 | | 2014 | | 2015 | | 2016 | | 2017 | | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2023 | |
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| ACT | 0 | 0 | 1 | 2.2 | 7 | 9.3 | 0 | 0 | 8 | 7.1 | 3 | 2.1 | 18 | 8.7 | 14 | 7.1 | 9 | 6.1 | 6 | 3.2 | 7 | 3.2 | **5** | **1.9** |
| NSW | 9 | 0.5 | 14 | 0.9 | 33 | 2.0 | 43 | 2.3 | 82 | 3.6 | 261 | 9.3 | 230 | 6.5 | 215 | 6.0 | 181 | 7.0 | 191 | 9.9 | 109 | 4.0 | **165** | **4.6** |
| Qld | 15 | 2.1 | 38 | 5.7 | 23 | 3.5 | 42 | 5.8 | 10 | 1.2 | 61 | 4.9 | 68 | 4.9 | 32 | 1.9 | 43 | 2.9 | 14 | 1.2 | 32 | 2.3 | **41** | **2.7** |
| SA | 1 | 0.7 | 6 | 2.8 | 1 | 0.5 | 7 | 2.8 | 68 | 19.5 | 46 | 12.8 | 7 | 3.0 | 11 | 2.0 | 1 | 0.3 | 3 | 1.0 | 3 | 0.7 | **17** | **2.9** |
| Tas. | 0 | 0 | 0 | 0 | 1 | 3.3 | 1 | 4.3 | 4 | 14.3 | 5 | 9.0 | 3 | 6.0 | 1 | 2.0 | 0 | 0 | 4 | 5.8 | 5 | 5.2 | **8** | **5.9** |
| Vic. | 34 | 2.7 | 35 | 2.3 | 33 | 2.3 | 30 | 1.8 | 93 | 5.4 | 304 | 13.5 | 217 | 8.3 | 161 | 6.2 | 29 | 1.7 | 59 | 3.1 | 144 | 5.8 | **159** | **5.8** |
| NT non-remote | 0 | 0 | 1 | 1.0 | 0 | 0 | 0 | 0 | 1 | 1.9 | 1 | 1.7 | 1 | 1.5 | 1 | 1.8 | 2 | 3.9 | 1 | 2.0 | 1 | 1.1 | **4** | **3.8** |
| NT remote | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | **0** | **0** |
| WA non-remote | 3 | 0.6 | 9 | 1.9 | 21 | 5.3 | 15 | 3.8 | 51 | 7.6 | 40 | 6.4 | 16 | 2.5 | 12 | 1.6 | 18 | 2.6 | 18 | 3.7 | 16 | 3.3 | **57** | **5.9** |
| WA remote | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.8 | 4 | 3.4 | 1 | 0.9 | 1 | 1.2 | 1 | 0.9 | 0 | 0 | 0 | 0 | **2** | **3** |
| Australia | 62 | 1.3 | 104 | 2.1 | 119 | 2.5 | 138 | 2.6 | 318 | 5.0 | 726 | 9.3 | 561 | 6.2 | 448 | 4.6 | 284 | 3.9 | 296 | 4.7 | 317 | 3.9 | 458 | 4.5 |

a ACT: Australian Capital Territory; NSW: New South Wales; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic.: Victoria; NT: Northern Territory; WA: Western Australia.

There were 22 isolates reported with ceftriaxone MIC values ≥ 0.125 mg/L in 2023: New South Wales (8); Victoria (8), Queensland (3); non-remote Western Australia (2) and South Australia (1). Fourteen isolates (14/22) with ceftriaxone MICs ranging from 0.125 to 1 mg/L had the *penA* allele 60.001 (one isolate with a partial match), which encodes key alterations in the penicillin binding protein 2 associated with ceftriaxone resistance, detected on genomic analysis by the NNN Laboratories. Public Health investigations were conducted at the jurisdictional level, with four of the fourteen cases reporting overseas contact or travel to the Asia Pacific.

Four of the eight isolates with ceftriaxone MIC values ≥ 0.125 mg/L reported from Victoria had an extensively drug resistant (XDR) profile20 with resistance to penicillin and ciprofloxacin and high-level azithromycin resistance (MIC value ≥ 256 mg/L). Jurisdictional investigations including genomics are ongoing, with the sequence type ST-16406 identified in all four isolates, the same sequence type reported in 2022,19 and where available reported Asia-Pacific contact.

### Azithromycin

Nationally, in 2023, azithromycin resistance was detected in 4.5% of isolates (Table 3), an increase from 3.9% in 2022.19 Since 2012, rates of azithromycin resistance increased from 1.3% to a peak of 9.3% in 2017, then declined to 3.9% in 2020 (Table 6). Rates of azithromycin-resistant NG were highest in non-remote Western Australia (5.9%), Tasmania (5.9%), Victoria (5.8%), and New South Wales (4.6%) (Tables 5 and 6). In 2023, twenty-seven isolates exhibited high-level resistance to azithromycin (MIC ≥ 256 mg/L), reported from Victoria (13), New South Wales (11), non-remote Western Australia (2) and Queensland (1).

### Penicillin

Penicillin resistance results from ß-lactamase production (i.e., penicillinase) and/or from the aggregation of chromosomally-controlled resistance mechanisms. These are denoted respectively as penicillinase-producing *N. gonorrhoeae* (PPNG) and chromosomally-mediated resistance to penicillin (CMRP).

In 2023, in Australia, 3,102 isolates (30.7%) were penicillin resistant (Table 3), a decrease from 2022 (38.8%).19 The proportion of penicillin-resistant isolates has fluctuated in the range 22% to 44% between 2008 and 2022.17 In 2023, of the 3,102 penicillin-resistant isolates, there were 861 (27.8%) with CMRP; 2,241 (72.2%) were PPNG.

#### Penicillin resistance in remote Australia

In 2023, there were 205 isolates tested from the Northern Territory, with 100 referred from remote areas (including Alice Springs, Katherine, Tennant Creek, and Arnhem Land region) and 105 from Darwin and surrounding urban areas (non-remote). In 2023, there were 1,038 isolates tested from Western Australia, with 71 referred from remote regions and 967 from urban and suburban Perth (non-remote).

Of the 100 isolates from remote Northern Territory, five were penicillin resistant, PPNG (5%). Of the 71 isolates from remote Western Australia, ten (14.1%) were penicillin resistant, of which four were CMRP and six were PPNG.

### Ciprofloxacin

In 2023, ciprofloxacin resistance was reported in 6,096 isolates (60.3%), lower than in 2022 (63.3%)19 (Table 3). Ciprofloxacin has not been recommended in Australia as first-line therapy for gonococcal infections since the late 1990s. As reported by the AGSP, the rate of ciprofloxacin resistance progressively declined in Australia since 2008, peaking at 71%, before reaching a nadir of 25.6% in 2018.7 The increase in ciprofloxacin resistance from 52.9% in 2021 to 63.3% in 2022 can be attributed to an extent to the expansion of the ST-7827 clone, particularly in New South Wales.18

### Tetracyclines

To optimise reporting of tetracycline resistance in *N. gonorrhoeae*, from 2018, NNN reference laboratories have performed tetracycline MIC testing where possible. This replaces historical breakpoint testing for high-level tetracycline-resistant *N. gonorrhoeae* (TRNG) (MIC ≥ 16 mg/L) reported by the AGSP as an epidemiological marker for plasmid-mediated resistance. Tetracycline resistance is defined as MIC ≥ 2 mg/L. Nationally in 2023, fifty-six percent of isolates (5,674/10,105) were tested, and 31% of tested isolates (1,755/5,674) were tetracycline resistant. Tetracycline resistance data are presented by jurisdiction and aggregated for Australia as shown in Table 7.

Table 7: Number and proportion (%) of gonococcal isolates with resistance to tetracycline (MIC ≥2 mg/L), Australia, 2023, by state or territory

| State or territory | Number of isolates tested 2023 | Tetracycline resistance MIC ≥ 2 mg/L | |
| --- | --- | --- | --- |
| n | % |
| Australian Capital Territory | 228 | 64 | 28% |
| New South Wales | 201 | 49 | 24% |
| Queensland | 1,479 | 524 | 35% |
| South Australiaa | NT | NT | NT |
| Tasmania | 136 | 53 | 39% |
| Victoria | 2,571 | 802 | 31% |
| Northern Territory non-remote | 6 | 0 | 0% |
| Northern Territory remote | 18 | 0 | 0% |
| Western Australia non-remote | 965 | 251 | 26% |
| Western Australia remote | 70 | 12 | 17% |
| Australia | 5,674 | 1,755 | 31% |

a NT: not tested.

### Spectinomycin

In 2023, all isolates tested (n = 9,174; 90.8%) were susceptible to spectinomycin.

### Gentamicin

In 2023, gentamicin susceptibility testing data was available for 5,328 isolates originating from the Australian Capital Territory, New South Wales, Tasmania, Western Australia and the Northern Territory. The median MIC value was 4 mg/L; and the range was ≤ 1.0—16 mg/L. There are no gentamicin breakpoints defined for *N. gonorrhoeae*.

# Discussion

In 2023, the number of notifications of *N. gonorrhoeae* infections in Australia was 40,429, an increase of 16% from the pre-pandemic notifications to the NNDSS in 2019 (34,743).9 The NNN jurisdictional reference laboratories reported data from clinical testing of 10,105 *N. gonorrhoeae* isolates (representing 25% of infections) from urban and remote settings in both public and private health sectors. The remote regions of Western Australia and the Northern Territory continue to report the highest rates of gonococcal disease, relatively low rates of AMR, and low numbers of isolates available for AST.

From 2016 to 2018, the proportion of isolates with ceftriaxone decreased susceptibility (MIC value ≥ 0.125 mg/L)15 reported by the AGSP remained stable in the range 0.04–0.06%. However, in 2019, this increased to 0.11% (Table 5) then further decreased during 2020–2021 coincident with public health containment measures for COVID-19. In 2022, the AGSP reported a surge in the number and proportion of isolates with ceftriaxone MIC values ≥ 0.06 mg/L, largely attributed to the expansion of a clone of limited genomic diversity of sequence type ST-7827 in 24/27 (89%) isolates detected in male and female patients in New South Wales. These ST-7827 isolates had a non-mosaic *penA* allele, and all were susceptible to azithromycin, but were resistant to ciprofloxacin (reflected in the increase in ciprofloxacin resistance in New South Wales, in the range 29–36% in the period 2015–2019 then increasing to 76% in 2022).18 In 2023, the detection of ST-7827 *N. gonorrhoeae* in New South Wales subsided. Similarly, in Norway, *N. gonorrhoeae* ST-7827 rates increased rapidly in the population from 2% to 20% in two years (2016–2018) and then waned.21

Of concern, in 2023 there were 22 isolates reported nationally by the AGSP with ceftriaxone MIC values ≥ 0.125 mg/L:15 New South Wales (8); Victoria (8); Queensland (3), Western Australia (2) and South Australia (1). Of these, 14/22 from multiple jurisdictions (Victoria (7), New South Wales (3); Queensland (3) and Western Australia (1)) were confirmed by whole genome sequencing to harbour the mosaic *penA* allele 60.001 (encoding key alterations in the penicillin binding protein 2 associated with ceftriaxone resistance). These 14 isolates had ceftriaxone MIC values ranged from 0.125 to 1.0 mg/L. Of these, where travel history was available, there was confirmed travel history or association with the Asia Pacific region. A 2022 report from the United Kingdom (UK),22 describing a surge in detection of *N. gonorrhoeae* isolates harbouring the *penA* 60.001 allele, heightened concerns regarding emergence of gonococcal AMR.

Four of the eight ceftriaxone MIC ≥ 0.125 mg/L isolates reported from Victoria in 2023 had an extensively drug resistant (XDR) profile20 (ceftriaxone MIC 0.25 mg/L; azithromycin MIC ≥ 256 mg/L), with all four harbouring the mosaic *penA* 60.001 allele. The first reports of XDR *N. gonorrhoeae* were from Australia (two unrelated cases, one with a travel history in the Asia-Pacific) and one from the UK (with travel link to Thailand) in 2018.23,24 On genomic analysis, there was limited diversity between the 2018 UK and Australian XDR isolates, suggesting these isolates belonged to the same gonococcal clone.25 In 2022, two further cases were reported, one in Austria with travel links in Cambodia,26 and another in the UK with contact in the Asia-Pacific.24 Genomic analysis found the 2022 UK and European isolates to be identical24 and related to the case reported in the UK in 2018. These findings strongly suggest these strains are in circulation in the Asia-Pacific.24 The detection of such isolates in Victoria is extremely concerning; further investigations at the jurisdictional level are ongoing and will be reported.

Azithromycin resistance has been reported by the AGSP since 2007. Following the introduction of dual therapy in 2014, resistance to azithromycin in all jurisdictions of Australia has been observed (Table 6), increasing from 2016, and peaking at 9.3% in 2017. However, rates halved in 2019 (4.6%), and have remained relatively stable for the last four years (Table 6). In 2023, azithromycin resistance was highest in non-remote Western Australia (5.9%), Tasmania (5.9%), Victoria (5.8%), and New South Wales (4.6%).

In 2013, high-level resistance (HLR; MIC ≥ 256 mg/L) to azithromycin in gonococci was reported for the first time. Since then, there have been sporadic reports of *N. gonorrhoeae* isolates with HLR to azithromycin in Australia annually; none were reported in 2021. In 2022, nine such isolates were reported nationally and notably this number increased to 27 in 2023, this being the highest number reported to date. These isolates were largely contributed from Victoria and New South Wales and the majority isolated from male patients. Data from the jurisdictions, where available, has indicated some of these were associated with overseas travel to South America, Africa and Europe.

In 2023, penicillin resistance was reported in 30.7% of isolates (3,102/10,105) (Table 3), an increase from 2020 (26.6%). The proportion of penicillin-resistant isolates has been reported in the range 22% to 44% between 2008 and 2022. In 2023, of the penicillin-resistant isolates, there were 861 isolates (27.8%) with CMRP; 2,241 isolates (72.2%) were PPNG. With regards to the isolates from remote regions, of the 100 isolates from remote Northern Territory, five were penicillin resistant, PPNG (5%). There were 71 isolates from remote Western Australia, ten (14.1%) were penicillin resistant, four with CMRP and six were PPNG.

In 2023, ciprofloxacin resistance was reported in 60.3% of tested isolates, lower than 63.3% in 2022 (Table 3).19 The rate of ciprofloxacin resistance reported in Australia had progressively declined since 2008 (71%) to 25.6% in 2018. The increase in ciprofloxacin resistance from 2021 can be attributed to an extent to the expansion of the ST-7827 clone, particularly in New South Wales.18 With regards to the remote regions of Australia, of the 100 isolates from remote Northern Territory, eight were ciprofloxacin resistant (8%), and of the 71 isolates from remote Western Australia, 16 were ciprofloxacin resistant (22.5%).

In 2023, gentamicin susceptibility testing data were available for 5,328 *N. gonorrhoeae* isolates from New South Wales, Tasmania, Western Australia, the Australian Capital Territory and the Northern Territory. The median MIC value was 4 mg/L; the range was ≤ 1.0—16 mg/L. There are no gentamicin breakpoints defined for *N. gonorrhoeae*. The inclusion of gentamicin as an indicator for ongoing surveillance by the AGSP is in line with the WHO Global Antimicrobial Resistance Surveillance System (GLASS).

Nationally in 2023, fifty-six percent of isolates (5,674/10,105) were tested for tetracycline resistance; 31% (1,755/5,674) were tetracycline resistant. Tetracycline resistance data are presented by jurisdiction and aggregated for Australia as shown in Table 7. The highest rate was reported from Tasmania (39%), with resistance reported in other jurisdictions (excluding remote Northern Territory and Western Australia) in the range 24–39%, noting there are no data from South Australia. There has been recent interest in the proportion of tetracycline resistance in NG in Australia, due to considerations of using this agent for possible pre- and post-exposure prophylaxis of bacterial sexually transmitted infections in high-risk populations.

A number of concerning observations are reported by the AGSP in 2023. Of the greatest concern are the surge in *N. gonorrhoeae* isolates detected nationally with the *penA* 60.001 allele; the detection of four isolates with an XDR profile from Victoria; and the increase in notifications of isolates with high level resistance to azithromycin from New South Wales and Victoria. Additional clinical, public health and laboratory investigations, including genomic analysis at the jurisdictional level, have been implemented as part of the response to these events. These include follow up, test of cure and investigations regarding travel history. The findings from this report underscore the ongoing importance of surveillance based on bacterial culture and AST of *N. gonorrhoeae*. These data are critically important to inform future therapeutic strategies; to monitor for the presence and spread of resistant isolates; and to detect instances of treatment failure.

# Acknowledgments

The NNN is supported by the Australian Government Department of Health and Aged Care to provide the AGSP. We thank the many laboratories, private and public, throughout Australia for referral of isolates for testing.

Members of the NNN in 2023 (and to whom isolates should be referred): Amy Jennison, Vicki Hicks, Helen Smith, Gino Micalizzi, Kerri Le and Rikki Graham (Queensland Public Health Microbiology, Forensic and Scientific Services, Coopers Plains, Queensland); Athena Limnios, Tiffany Hogan, Ratan Kundu, Prashanthi Sai Krishnan, Jasmin El-Nasser, Sebastiaan J van Hal and Monica M Lahra (WHO CC for STI and AMR New South Wales Health Pathology Department of Microbiology, The Prince of Wales Hospital, Randwick, New South Wales and School of Medical Sciences, Faculty of Medicine, the University of New South Wales, Kensington, New South Wales); Kerrie Stevens, Samantha Tawil, Paula Roydhouse, Angela Todd and Benjamin P Howden (The Microbiological Diagnostic Unit (PHL), Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria); Megan Hodgson, Lex Leong, Casey Moore and Ivan Bastian (SA Pathology, South Australia);, Hui Leen Tan and David Speers (Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine, Fiona Stanley Hospital, Western Australia); Belinda McEwan (Department of Microbiology and Infectious Diseases, Royal Hobart Hospital, Hobart, Tasmania); Kevin Freeman and Rob Baird (Microbiology Laboratory, Territory Pathology, Royal Darwin Hospital, Tiwi, Northern Territory); and Susan Bradbury, Cherie O’Brien, Michelle McKeown and Peter Collignon (Microbiology Department, The Canberra Hospital, Garran, Australian Capital Territory).

# Author details

Monica M Lahra1,2

Sebastiaan van Hal3,4

Tiffany R Hogan1

1. Neisseria Reference Laboratory and World Health Organization Collaborating Centre for STI and AMR, Sydney. NSW Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031, Australia
2. School of Medical Sciences, Faculty of Medicine, The University of New South Wales, NSW, 2052, Australia
3. New South Wales Health Pathology, Microbiology, Royal Prince Alfred Hospital Camperdown, NSW, Australia
4. School of Medicine, University of Sydney

Corresponding author

Professor Monica M Lahra

World Health Organization Collaborating Centre for STI and AMR, Sydney and, Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031

School of Medical Sciences, Faculty of Medicine, the University of New South Wales, NSW, 2052 Australia

Telephone: +61 2 9382 3678

Facsimile: +61 2 9382 3720

Email: monica.lahra@health.nsw.gov.au

# References

1. Lahra MM, George CR, Whiley DM. The Australian Gonococcal Surveillance Programme 1979–2017. *Microbiol Aust*. 2017;38(4):175–9. doi: https://doi.org/10.1071/MA17062.
2. Lahra MM, Martin I, Demczuk W, Jennison AV, Lee KI, Nakayama SI et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant *Neisseria gonorrhoeae* strain. *Emerg Infect Dis*. 2018;24(4):735–40. doi: https://doi.org/10.3201/eid2404.171873.
3. Whiley DM, Jennison A, Pearson J, Lahra MM. Genetic characterisation of *Neisseria gonorrhoeae* resistant to both ceftriaxone and azithromycin. *Lancet Infect Dis*. 2018; 18(7):717–8. doi: https://doi.org/10.1016/S1473-3099(18)30340-2.
4. European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia. [Internet.] Stockholm: ECDC; 7 May 2018. Available from: https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-extensively-drug-resistant-xdr-neisseria-gonorrhoeae-united.
5. Tapsall JW, Limnios EA, Murphy DM. Analysis of trends in antimicrobial resistance in *Neisseria gonorrhoeae* isolated in Australia, 1997–2006. *J Antimicrob Chemother*. 2008;61(1):150–5. doi: https://doi.org/10.1093/jac/dkm434.
6. Hanrahan JK, Hogan TR, Buckley C, Trembizki E, Mitchell H, Lau CL et al. Emergence and spread of ciprofloxacin-resistant *Neisseria gonorrhoeae* in New South Wales, Australia: lessons from history. *J Antimicrob Chemother*. 2019;74(8):2214–9. doi: https://doi.org/ 10.1093/jac/dkz182.
7. Armstrong BH, Limnios A, Lewis DA, Hogan T, Kundu R, Ray S et al. Is gentamicin a viable therapeutic option for treating resistant *Neisseria gonorrhoeae* in New South Wales? *Commun Dis Intell (2018)*. 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.12.
8. King J, McManus H, Kwon JA, Gray R, McGregor S, Kirby Institute. *HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2023*. Sydney: University of New South Wales, Kirby Institute; 2023. Available from: https://www.kirby.unsw.edu.au/sites/default/files/documents/Annual-Surveillance-Report-2023\_STI.pdf.
9. Australian Government Department of Health and Aged Care. National Notifiable Diseases Surveillance System (NNDSS) data visualisation tool. [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 14 December 2022. [Accessed on 13 March 2024.] Available from: https://www.health.gov.au/resources/apps-and-tools/national-notifiable-diseases-surveillance-system-nndss-data-visualisation-tool.
10. Northern Territory Government Department of Health (NT Health), Centre for Disease Control. *Public Health Alert: Penicillinase-producing Neisseria gonorrhoeae (PPNG): changes treatment recommendations for gonorrhoea NT wide*. Darwin: NT Health; 23 October 2023. Available from: https://health.nt.gov.au/\_\_data/assets/pdf\_file/0006/1288635/health-alert-penicillinase-producing-neisseria-gonorrhoeae-231023.pdf.
11. Lahra MM, Hogan TR, Armstrong BH, for the National Neisseria Network. Australian Gonococcal Surveillance Programme Annual Report, 2021. *Commun Dis Intell (2018)*. 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.52.
12. Tapsall J, World Health Organization (WHO) Anti-Infective Drug Resistance Surveillance and Containment Team. *Antimicrobial resistance in Neisseria gonorrhoeae*. Geneva: WHO; 2001. Available from: https://apps.who.int/iris/handle/10665/66963.
13. Goire N, Freeman K, Tapsall JW, Lambert SB, Nissen MD, Sloots TP et al. Enhancing gonococcal antimicrobial resistance surveillance: a real-time PCR assay for detection of penicillinase-producing *Neisseria gonorrhoeae* by use of noncultured clinical samples. *J Clin Microbiol*. 2011;49(2):513–8. doi: https://doi.org/10.1128/JCM.02024-10.
14. Speers DJ, Fisk RE, Goire N, Mak DB. Non-culture *Neisseria gonorrhoeae* molecular penicillinase production surveillance demonstrates the long-term success of empirical dual therapy and informs gonorrhoea management guidelines in a highly endemic setting. *J Antimicrob Chemother*. 2014;69(5):1243–7. doi: https://doi.org/10.1093/jac/dkt501.
15. World Health Organization (WHO). *Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae*. Geneva: WHO; 2012. Available from: https://apps.who.int/iris/handle/10665/44863.
16. Tapsall JW, Australian Gonococcal Surveillance Programme. Use of a quality assurance scheme in a long-term multicentric study of antibiotic susceptibility of *Neisseria gonorrhoeae*. *Genitourin Med*. 1990;66(1):8–13. doi: https://doi.org/10.1136/sti.66.1.8.
17. Australian Gonococcal Surveillance Programme (AGSP) annual reports 2008 to 2021. Available from: Australian Government Department of Health and Aged Care. Australian Gonococcal Surveillance Programme (AGSP) annual reports. [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 2023. [Accessed on 19 March 2024.] https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-gonoanrep.htm.
18. van Hal SJ, Whiley DM, Le T, Ray S, Kundu RL, Kerr E et al. Rapid expansion of *Neisseria gonorrhoeae* ST-7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype. *J Antimicrob Chemother*. 2023;78(9):2203–8. doi: https://doi.org/10.1093/jac/dkad221.
19. Lahra MM, van Hal SJ, Hogan TR, for the National Neisseria Network. Australian Gonococcal Surveillance Programme Annual Report, 2022. *Commun Dis Intell (2018)*. 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.45.
20. Unemo M, Tapsall JW, Ndowa F, Lewis DA. Meeting the public health challenge of multidrug -and extensively drug-resistant *Neisseria gonorrhoeae*. *Expert Rev Anti Infect Ther*. 2009;7(7):821–34. doi: https://doi.org/10.1586/eri.09.63.
21. Osnes MN, Didelot X, Korne-Elenbaas J, Alfsnes K, Brynildsrud OB, Syversen G et al. Sudden emergence of a *Neisseria gonorrhoeae* clade with reduced susceptibility to extended-spectrum cephalosporins, Norway. *Microb Genom*. 2020;6(12):mgen000480. doi: https://doi.org/10.1099/mgen.0.000480.
22. Day M, Pitt R, Mody N, Saunders J, Rai R, Nori A et al. Detection of 10 cases of ceftriaxone-resistant *Neisseria gonorrhoeae* in the United Kingdom, December 2021 to June 2022. *Euro Surveill*. 2022;27(46):2200803. doi: https://doi.org/10.2807/1560-7917.ES.2022.27.46.2200803.
23. European Centre for Disease Prevention and Control (ECDC). R*apid risk assessment: extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia: 7 May 2018*. Stockholm: ECDC; 7 May 2018. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/RRA-Gonorrhoea,%20Antimicrobial%20resistance-United%20Kingdom,%20Australia.pdf.
24. Whiley DM, Jennison A, Pearson J, Lahra MM. Genetic characterisation of *Neisseria gonorrhoeae* resistant to both ceftriaxone and azithromycin. *Lancet Infect Dis*. 2018;18(7):717–8. doi: https://doi.org/10.1016/S1473-3099(18)30340-2.
25. Jennison AV, Whiley D, Lahra MM, Graham RM, Cole MJ, Hughes G et al. Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant *Neisseria gonorrhoeae* cases, United Kingdom and Australia, February to April 2018. *Euro Surveill*. 2019;24(8):1900118. doi: https://doi.org/10.2807/1560-7917.ES.2019.24.8.1900118.
26. Pleininger S, Indra A, Golparian D, Heger F, Schindler S, Jacobsson S et al. Extensively drug-resistant (XDR) *Neisseria gonorrhoeae* causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. *Euro Surveill*. 2022;27(24):2200455. doi: https://doi.org/10.2807/1560-7917.ES.2022.27.24.2200455.

© Commonwealth of Australia as represented by the Department of Health and Aged Care

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (CC BY-NC-ND) available from https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode (Licence). You must read and understand the Licence before using any material from this publication.

Restrictions

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found on the Department of Prime Minister and Cabinet website;
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

Disclaimer

Opinions expressed in *Communicable Diseases Intelligence* are those of the authors and not necessarily those of the Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

Enquiries

Enquiries regarding any other use of this publication should be addressed to the CDI Editor at: cdi.editor@health.gov.au.

Communicable Diseases Network Australia

Communicable Diseases Intelligence contributes to the work of the [Communicable Diseases Network Australia](http://www.health.gov.au/cdna).

About Communicable Diseases Intelligence

*Communicable Diseases Intelligence* (CDI) is a peer-reviewed scientific journal published by the Health Security & Emergency Management Division, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

**Editor**: Christina Bareja • **Deputy Editor**: Simon Petrie • **Design and Production**: Lisa Thompson

**Editorial Advisory Board**: David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk and Meru Sheel

Submit an Article

Submit your next communicable disease related article to CDI for consideration. [Information for authors](https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-cdi-auth_inst.htm) and details on how to [submit your publication](https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-cdi-auth_inst.htm#submission_package) is available on our website, or by email at [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

Contact us

Communicable Diseases Intelligence (CDI)

Health Security & Emergency Management Division

Department of Health and Aged Care

GPO Box 9848, CANBERRA ACT 2601

Website: [www.health.gov.au/cdi](http://www.health.gov.au/cdi)

Email: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)